Skip to main content

Table 5 Sensitivity analysis of adjusted odds ratio and 95% confidence interval for new AMI hospitalization and NSAIDs use on different definition of case and control period

From: Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence

 

days before index date

Case period

Control period

1-30

91-120

8-30

98-120

1-30

61-90

 

aOR*

95%CI

aOR*

95%CI

aOR*

95%CI

ns-NSAIDs

      

Oral overall

1.42

1.29 - 1.56

1.19

1.08 - 1.31

1.48

1.35 - 1.63

Parental overall

3.35

2.50 - 4.47

1.85

1.34 - 2.57

2.81

2.13 - 3.70

Oral

      

celecoxib

1.42

0.99 - 2.04

1.19

0.83 - 1.71

1.03

0.73 - 1.46

ketorolac

2.02

1.00 - 4.09

2.58

1.25 - 5.33

2.37

1.23 - 4.59

diclofenac

1.29

1.13 - 1.47

1.13

0.99 - 1.30

1.46

1.28 - 1.66

Parenteral

      

ketorolac

4.27

2.90 - 6.29

1.98

1.25 - 3.13

2.90

2.05 - 4.10

ketoprofen

2.34

1.31 - 4.19

1.77

0.97 - 3.22

1.98

1.12 - 3.50

diclofenac

1.88

0.95 - 3.75

1.14

0.53 - 2.47

2.35

1.09 - 5.08

  1. aOR = adjusted odds ratio; 95%CI = 95% confidence interval; ns-NSAIDs = non-selective NSAIDs
  2. * Conditional logistic regression adjusted for time-varying confounding variables of discordant use of antihypertensive agents, angiotensin converting enzyme inhibitors or aldosterone receptor blockers, calcium channel blockers, statins, insulin, sulfonylurea, thiazolidinedione, and aspirin between case and control period.